Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-16
2005-08-16
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266220, C544S256000, C544S291000
Reexamination Certificate
active
06930113
ABSTRACT:
The present invention describes novel nitrosated and/or nitrosylated phosphodiesterase inhibitors, and novel compositions containing at least one nitrosated and/or nitrosylated phosphodiesterase inhibitor, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one phosphodiesterase inhibitor, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing diseases induced by the increased metabolism of cyclic guanosine 3′,5′-monophosphate (cGMP), such as hypertension, pulmonary hypertension, congestive heart failure, renal failure, myocardial infraction, stable, unstable and variant (Prinzmetal) angina, atherosclerosis, cardiac edema, renal insufficiency, nephrotic edema, hepatic edema, stroke, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, dementia, immunodeficiency, premature labor, dysmenorrhoea, benign prostatic hyperplasis (BPH), bladder outlet obstruction, incontinence, conditions of reduced blood vessel patency, e.g., postpercutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, allergic rhinitis, glucoma, and diseases characterized by disorders of gut motility, e.g., irritable bowel syndrome (IBS).
REFERENCES:
patent: 4308278 (1981-12-01), Schneider et al.
patent: 4963541 (1990-10-01), Brooks et al.
patent: 5171217 (1992-12-01), March et al.
patent: 5190967 (1993-03-01), Riley
patent: 5196426 (1993-03-01), Saccomano et al.
patent: 5223504 (1993-06-01), Noverola et al.
patent: 5254575 (1993-10-01), Pick et al.
patent: 5340827 (1994-08-01), Beeley et al.
patent: 5380758 (1995-01-01), Stamler et al.
patent: 5426107 (1995-06-01), Bell et al.
patent: 5438060 (1995-08-01), Miyazaki et al.
patent: 5439938 (1995-08-01), Snyder et al.
patent: 5491147 (1996-02-01), Boyd et al.
patent: 5492911 (1996-02-01), Stief
patent: 5543430 (1996-08-01), Kaesemeyer
patent: 5545647 (1996-08-01), Tanaka et al.
patent: 5565466 (1996-10-01), Gioco et al.
patent: 5583101 (1996-12-01), Stamler et al.
patent: 5614627 (1997-03-01), Takase et al.
patent: 5618814 (1997-04-01), Heckel et al.
patent: 5645839 (1997-07-01), Chobanian et al.
patent: 5646181 (1997-07-01), Fung et al.
patent: 5693652 (1997-12-01), Takase et al.
patent: 5698589 (1997-12-01), Allen
patent: 5716993 (1998-02-01), Ozaki et al.
patent: 5731339 (1998-03-01), Lowrey
patent: 5767160 (1998-06-01), Kaesemeyer
patent: 5824669 (1998-10-01), Garvey et al.
patent: 5849741 (1998-12-01), Watanabe et al.
patent: 5859006 (1999-01-01), Daugan
patent: 5869516 (1999-02-01), Arlt et al.
patent: 5874437 (1999-02-01), Garvey et al.
patent: 5877216 (1999-03-01), Place et al.
patent: 5932538 (1999-08-01), Garvey et al.
patent: 5958926 (1999-09-01), Garvey et al.
patent: 5973011 (1999-10-01), Noack et al.
patent: 5981527 (1999-11-01), Daugan et al.
patent: 6007824 (1999-12-01), Duckett et al.
patent: 6037346 (2000-03-01), Doherty, Jr. et al.
patent: 6143746 (2000-11-01), Daugan et al.
patent: RE37234 (2001-06-01), Garvey et al.
patent: 6331543 (2001-12-01), Garvey et al.
patent: 6464044 (2002-10-01), Suganuma
patent: 0 252 721 (1988-01-01), None
patent: 0 352 960 (1990-01-01), None
patent: 0 442 204 (1991-08-01), None
patent: 0 463 756 (1992-01-01), None
patent: 0 506 194 (1992-09-01), None
patent: 2547501 (1984-12-01), None
patent: 9307149 (1993-04-01), None
patent: 9501338 (1995-01-01), None
patent: WO 95/09636 (1995-04-01), None
patent: WO 95/26725 (1995-10-01), None
patent: WO 96/25184 (1996-08-01), None
patent: 9703675 (1997-02-01), None
patent: 9703985 (1997-02-01), None
patent: WO 97/34871 (1997-09-01), None
patent: WO 97/39760 (1997-10-01), None
patent: 9743287 (1997-11-01), None
patent: 9817668 (1998-04-01), None
patent: 9819672 (1998-05-01), None
patent: 9849166 (1998-11-01), None
patent: 9852569 (1998-11-01), None
patent: 9921558 (1999-05-01), None
patent: 9921562 (1999-05-01), None
patent: 9922731 (1999-05-01), None
patent: 9930697 (1999-06-01), None
Boolell et al,International Journal of Impotence Research, 8:47-52 (1996).
Krane et al,New England Journal of Medicine, 321(24):1648-1659 (1989).
Trigo-Rocha et al,Neurourol. Urodyn., 13(1):71-80 (1994).
Sparwasser et al,J. Urol., 152:6, Pt. 1, pp. 2159-2163 (1994).
Terrett et al,Bioorg. Med. Chem. Lett., 6(15):1819-1824 (1996).
Park et al,Biochem. Biophys. Res. Commun., 249(3):612-617 (1998).
Mathers et al,European Urology, 35(suppl 2):67 (abstract 266) (1999).
Zorgniotti et al,Int. J. Impotence Res., 6:33-36 (1994).
Chemical Abstracts, vol. 120, No. 1, Abstract No. 5451d (1994).
Martel et al, Drugs of the Future, 22(2):138-143 (1997).
Boolell et al, British Journal of Urology, 78(2):257-261 (1996).
Chemical Abstracts, vol. 116, No. 1, Abstract No. 4477 (Jan. 6, 1992).
Chemical Abstracts, vol. 125, No. 15, Abstract No. 191382 (Oct. 7, 1996).
Chemical Abstracts, vol. 123, No. 1, Abstract No. 574 (Jul. 3, 1995).
Chemical Abstracts, vol. 120, No. 25, Abstract No. 315630 (Jun. 20, 1994).
Chemical Abstracts, vol. 121, No. 7, Abstract No. 73410 (Aug. 15, 1994).
Patnaik et al, Indian Journal of Pharmacology, 11(2)S 139-142 (1979).
Agarwal et al, Indian Journal of Chemistry, 29B:80-84 (1990).
Saxena et al, QSAR Strategies Des. Bioact. Compd., Proc. Eur. Symp, Quent. Struct. Act. Relat., 5th(1985), Meeting Date 1984, pp. 361-365.
de Tejada Inigo Saenz
Earl Richard A.
Garvey David S.
Khanapure Subhash P.
Nitromed Inc.
Raymond Richard L.
Wilmer Cutler Pickering Hale and Dorr LLP
LandOfFree
Nitrosated and nitrosylated phosphodiesterase inhibitors,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitrosated and nitrosylated phosphodiesterase inhibitors,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrosated and nitrosylated phosphodiesterase inhibitors,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3480995